39 results about "Multiple administration" patented technology

The invention discloses a method for evaluating the bioavailability in combined application of fuke qianjin tablets and antibiotics. According to the method, the concentration of a drug to be detected in a blood plasma sample is detected, the pharmacokinetic parameters are calculated by using an ADAPT 5.1 software inverse Gaussian model, and each group of the parameters are subjected to statistical analysis with SPSS software so as to complete the evaluation, wherein the blood plasma sample is obtained after the single administration of antibiotic drugs or the combined administration of fuke qianjin tablets and antibiotics, the concentration of the drug to be detected is the concentration of the antibiotic drug, and the method for detecting the concentration of the drug to be detected in the blood plasma sample is a HPLC-ECD method or HPLC-ESI-MS method. According to the present invention, the pharmacokinetic evaluation method for the multiple administration of fuke qianjin tablets and azithromycin in chronic pelvic inflammatory disease rats is established, and the reliable method for evaluating the rationality of the combined administration of fuke qianjin tablets and azithromycin is achieved; and with the evaluation method, the pharmacokinetic rule of fuke qianjin tablets and azithromycin in chronic pelvic inflammatory disease rats can be successfully obtained, the scientific basis can be provided for the reasonable clinical application of fuke qianjin tablets and azithromycin, and the reference can be provided for the subsequent related research.

The invention discloses a tissue factor-based tumor polypeptide vaccine, which is an AnsB-TF fusion protein formed by expressing a sequence fragment containing an epitope target in a human TF gene. The preparation method and application of the tumor polypeptide vaccine are also disclosed. In the present invention, the TF polypeptide fragment containing the epitope target is connected with the AnsB carrier by means of genetic engineering, and a tumor polypeptide vaccine with tissue factor as the target antigen epitope is obtained. The vaccine can prevent and treat tumors through active immunization against TF epitope targets. This active immunization can not only completely block the effect of TF on the tumor surface, but also avoid the trouble of multiple administrations.

A drug delivery formulation for treating a mental illness or a central nervous system disorder is disclosed. The drug delivery formulation includes a microcapsule containing a biodegradable polymer and a drug and a crosslinked hydrogel and a method for preparing the same. The drug delivery formulation can slowly release a drug at a constant rate without a burst of drug release in the early stage of drug administration to maintain a constant blood drug level over a long period of time and thus enjoys the advantage of preventing excessive initial release of drug, thereby obtaining a desirable sustained release profile by single administration without necessity for multiple administrations divided at regular time intervals.

The invention discloses a high-efficiency, targeted drug-loaded nano-micelle and its preparation method and application. The preparation steps are: (1) dissolving the amphiphilic block copolymer in an organic solvent, and then adding a small-molecule anti-leukemia drug Hydrochloride, after fully dissolved and mixed, add triethylamine to remove hydrochloric acid to form a small molecule anti-leukemia drug, and then add it to PBS buffer to form nanomicelles with inner core encapsulated drug and outer shell hydrophilic; after dialysis, dry , to obtain drug-loaded nanomicelles; the polydopamine modification method is used to modify the specific antibody against the leukemia cell surface antigen to achieve targeting. The particle size of the drug-loaded nano-micelle prepared by the invention is 50-100nm, showing good monodispersity, high drug-loading capacity and encapsulation efficiency, simple targeting modification steps, and good targeting leukemia cell killing effect , while for normal cells, it has high biological safety and can achieve slow release, avoiding the disadvantages of long-term and multiple administrations.